PCAS : OBTAINS THE "INNOVATIVE BUSINESS" LABEL AWARDED BY BPIFRANCE

PCAS becomes eligible for investment by French Innovation Funds (FCPI)

Longjumeau, 26^th May 2015: PCAS (Euronext Paris: PCA), specialists in the development and production of complex molecules for Life Sciences and Innovative Technologies, has obtained the "Innovative Business" label awarded by Bpifrance.

This label rewards the many years of service PCAS has given to research & development through dedicated programmes and partnerships forged with world leaders in health and leading-edge technologies, two fast-growing fields with strong potential.

Obtaining this label for a renewable period of 3 years confirms the ability of French Innovation Funds (FCPI) to invest in the capital of PCAS and of their subscribers to benefit from the corresponding tax advantages.

Mr Vincent Touraille, CEO of PCAS, said: "We are very happy that PCAS has been recognised as an "Innovative Business" by Bpifrance. This is proof of our Group's capacity for innovation, its ongoing work in R&D and its recognised expertise in rapidly growing, front-line sectors of activity. This label means that French Innovation Funds can now buy shares in the company, thus widening our base of potential investors."

Next financial publication:
Half-Year Sales, 28 July 2015

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €166 million in 2014 and employs nearly 900 people in six countries.
To find out more about PCAS, visit www.pcas.com:
http://www.pcas.com.